Topic:

M&A

Latest Headlines

Latest Headlines

Nicox adds to eye-drug pipeline with $120M buyout deal for Aciex

In a deal designed to beef up its pipeline of ophthalmology drugs, France's Nicox has snapped up Boston-based Aciex for $65 million in newly issued shares and up to $55 million in contingent value rights. Those CVRs are structured to pay off Aciex's investors in large part based on the success of Aciex's drug AC-170, which has been in Phase III studies for allergic conjunctivitis.

Takeda's chief-in-waiting sees big M&A in the drugmaker's future

Christophe Weber is next in line for the throne at Takeda, and the former GlaxoSmithKline exec has a mind to grow the Japanese pharma through dealmaking, hoping to refill the in-transition company's pipeline and expand in emerging markets.

Roche's Genentech bags game-changing breast cancer drug in $1.7B deal

Just a year after J&J swooped in to buy up Aragon's game-changing work on prostate cancer in a billion-dollar deal, Roche's Genentech has followed up to buy what remained: a closely-related breast cancer program that promises to change the way that disease is treated.

Allergan trots out buybacks, deals and cuts in new offensive against Valeant buy

Allergan CEO David Pyott last week said his goal was to give shareholders "most of what they want" to keep them on his side of a takeover battle with Valeant Pharmaceuticals. Now, Allergan is trying to do just that, weighing a share buyback as part of a larger plan to dodge the Canadian pharma's hostile advances.

Paratek absorbs the troubled Transcept in a reverse merger

Long since shelving an attempt to go public, antibiotics developer Paratek Pharmaceuticals has signed a deal that will give it a Wall Street debut after all, planning a reverse merger with the struggling Transcept Pharmaceuticals and picking up a $93 million investment along the way.

Bluebird bio snares gene-editing tech in $156M buyout deal

The gene therapy pioneer bluebird bio has snapped up a biotech outfit skilled in gene-editing and cell-signaling tech in a deal valued at up to $156 million, including about $16 million worth of its stock.

AbbVie's gaze puts the brakes on Shire's plans for major M&A

This year's explosion of pharma deals, both real and rumored, has put a spotlight on the U.K.'s complicated, far-reaching rules on corporate takeovers, and AbbVie's $46 billion pursuit of Shire has teased out a new wrinkle. Under local law, the Irish-headquartered Shire is unable to make any big buyouts of its own until AbbVie's pitching period expires, a provision that has hamstrung the company's deal-friendly ethos, CEO Flemming Ornskov said.

Stryker to buy Small Bone Innovations for up to $375M

Stryker will add the world's only PMA-approved, cementless, three-piece total ankle replacement system to its portfolio with its acquisition of Pennsylvania's Small Bone Innovations for up to $375 million in cash, the company announced June 30.

Allergan's poison pill can't stop Valeant from calling shareholders to a vote

Valeant has cleared another hurdle in its quest to buy Allergan. The key next step: a special shareholders meeting, where Valeant will try to shake up the company's board and overturn its acquisition defenses to get a $53 billion deal done.

Shire CEO's buyout plans thwarted when AbbVie came calling

Shire CEO Flemming Ornskov is none too happy about AbbVie's repeated attempts to buy his company for $46 billion. Shire has snubbed AbbVie's advances three times since April, and under U.K. takeover rules, the Chicago company has until July 18 to make another bid or leave the Irish company alone. Problem is, AbbVie's ongoing pursuit is preventing Shire from making acquisitions of its own--a goal the company had been pursuing aggressively.